| Quarterly revenue contribution from AHCO's capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year-over-year growth contribution by Q4 2026. | ramping throughout 2026, peaking at low double-digits by Q4 2026 | 2026-01-01 | 2026-12-31 | The timing and magnitude of this revenue ramp drive full-year revenue growth and margin expansion; faster-than-expected ramp is bullish, while a slower or smaller ramp is bearish. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | | 1.0 | 0.0037 | 2026-02-28 | False | | | | | Theme composer | | |
| AHCO plans the rollout of successful AI pilots (order intake AI and conversational AI for PAP self-scheduling) to additional regions. | in 2026 | 2026-01-01 | 2026-12-31 | Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | | 1.0 | 0.0037 | 2026-02-28 | False | | | | | Theme composer | | |
| The CMS competitive bidding program's final rule and subsequent contract awards/implementation for the next round of bidding are expected. | upcoming round of competitive bidding (timing uncertain in 2026) | 2026-01-01 | 2026-12-31 | The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth, while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory. | Theme | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | | 1.0 | 0.0045 | 2026-02-28 | False | | | | | Theme composer | | |
| AHCO is pursuing and potentially closing tuck-in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, with associated revolver usage/paydown. | through 2026 | 2026-02-24 | 2026-12-31 | Small acquisitions can smooth transitions and add local capacity; conversely, additional draws or mis-timed purchases could elevate leverage or integration risk and pressure near-term liquidity and margins. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | | 1.0 | 0.0037 | 2026-02-28 | False | | | | | Theme composer | | |
| Quarterly revenue contribution from the capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year‑over‑year growth contribution by Q4 2026. | ramping throughout 2026, peaking at low double‑digits by Q4 2026 | 2026-01-01 | 2026-12-31 | The timing and magnitude of this revenue ramp drive full‑year revenue growth and margin expansion; faster-than-expected ramp is bullish (greater operating leverage), while a slower or smaller ramp is bearish (prolonged margin pressure and higher net leverage). | Ticker | | | | | | | | | | | | | | | earnings_transcript | AHCO (ticker) | AHCO_8190a9c8 | 2026-02-24 |
| Rollout of successful AI pilots (order intake AI and conversational AI for PAP self‑scheduling) to additional regions. | in 2026 | 2026-01-01 | 2026-12-31 | Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance, but rollout delays or underperformance would limit anticipated cost savings. | Ticker | | | | | | | | | | | | | | | earnings_transcript | AHCO (ticker) | AHCO_5c48eab9 | 2026-02-24 |
| Effectiveness of diabetes segment recovery initiatives (expanded diabetes sales force and pharmacy/channel investments) to drive a rebound in CGM new starts and continued pump growth. | later in 2026 | 2026-07-01 | 2026-12-31 | Diabetes performance is a key swing factor for organic growth and valuation; a tangible rebound in new starts would be bullish (restores a previously weak segment and supports guidance), while persistent softness would reinforce downside risk from secular pressures (including GLP‑1 adoption) and hurt revenue and margin outlooks. | Ticker | | | | | | | | | | | | | | | earnings_transcript | AHCO (ticker) | AHCO_00fc6f4a | 2026-02-24 |
| Pursuit and potential closing of tuck‑in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, and associated revolver usage/paydown. | through 2026 | 2026-02-24 | 2026-12-31 | Small acquisitions can smooth transitions and add local capacity (bullish if accretive and enables faster ramp); conversely, additional draws or mis‑timed purchases could elevate leverage or integration risk and pressure near‑term liquidity and margins. | Ticker | | | | | | | | | | | | | | | earnings_transcript | AHCO (ticker) | AHCO_e7c66252 | 2026-02-24 |
| CMS competitive bidding program final rule and subsequent contract awards/implementation for the next round of bidding. | upcoming round of competitive bidding (timing uncertain in 2026) | 2026-01-01 | 2026-12-31 | The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth (share gains), while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory (bearish). | Theme | | | | | | | | | | | | | | | earnings_transcript | AHCO (ticker) | AHCO_2dab6ea0 | 2026-02-24 |
| Large-scale rollout of the 5008X CAREsystem and high-volume hemodiafiltration (HV-HDF) therapy in U.S. clinics, targeting 20% of the installed base in 2026. | in 2026, target of replacing around 20% of the installed base in our own clinics this year | 2026-01-01 | 2026-12-31 | This strategic initiative is expected to improve patient outcomes, increase operational efficiencies, and strengthen FMS's competitive position, but will incur OpEx headwinds in 2026. Successful execution is crucial for future growth and market share. | Ticker | | | | | | | | | | | | | | | earnings_transcript | FMS (ticker) | FMS_a8b53d93 | 2026-02-24 |
| Phasing out of temporary TDAPA (Transitional Drug Add-on Payment Adjustment) benefits for phosphate binders and antimicrobial catheter solutions. | start to phase out in 2026, stronger first half of 2026 before TDAPA benefits begin to phase out in the second half of 2026 | 2026-07-01 | 2026-12-31 | These benefits provided a significant positive contribution to earnings in 2025. Their phase-out will create a regulatory headwind of EUR 150M-EUR 200M in 2026, impacting profitability, with uncertainty around the exact erosion of branded pricing and future bundle payments. | Ticker | | | | | | | | | | | | | | | earnings_transcript | FMS (ticker) | FMS_b10690dc | 2026-02-24 |
| Continued negative impact from volume-based procurement and other regulatory policies in China on the Care Enablement segment. | expected to impact 2026, China remains challenging, and we are assuming moderately negative impact as we address regulatory policy changes and review our portfolio and strategy accordingly | 2026-01-01 | 2026-12-31 | These policies weighed on revenue and earnings in Q4 2025 and are expected to continue to negatively impact the segment's performance in 2026, with the magnitude dependent on FMS's strategic adjustments. | Ticker | | | | | | | | | | | | | | | earnings_transcript | FMS (ticker) | FMS_ed8c2ef3 | 2026-02-24 |
| Expiry of extended tax subsidies for Affordable Care Act (ACA) contracts. | 2026 outlook, regulatory headwinds from the expiry of the extended tax subsidies for ACA contracts | 2026-01-01 | 2026-12-31 | This regulatory headwind is expected to negatively impact earnings development, contributing to the EUR 150M-EUR 200M regulatory impact in 2026, with the full extent of the financial impact still being assessed. | Ticker | | | | | | | | | | | | | | | earnings_transcript | FMS (ticker) | FMS_9d8ae73c | 2026-02-24 |
| Recovery of U.S. same-market treatment growth (SMTG) from flat in 2026 towards the historical 2%+ baseline. | returning to 2%-plus as mortality normalizes and patient outflows improve, gradually improve over time to get back to that 2% plus | 2026-01-01 | 2028-12-31 | SMTG is a critical driver of revenue and operating leverage. A sustained recovery would signal normalization of patient mortality and successful strategic initiatives, positively impacting long-term growth and valuation. | Ticker | | | | | | | | | | | | | | | earnings_transcript | FMS (ticker) | FMS_5e50f090 | 2026-02-24 |
| Realization of an additional EUR 400 million in sustainable savings from the accelerated FME25+ transformation program by the end of 2027, with EUR 250 million incremental savings expected in 2026. | for the years '26 and 2027 for a total of EUR 1.2 billion of sustainable savings by the end of 2027, incremental FME25+ savings of EUR 250 million with related onetime cost of EUR 350 million in 2026 | 2026-01-01 | 2027-12-31 | This program is a key driver of profitability improvements, aiming for EUR 1.2 billion in total sustainable savings by 2027. Successful execution will significantly boost margins and earnings, offsetting inflationary pressures. | Ticker | | | | | | | | | | | | | | | earnings_transcript | FMS (ticker) | FMS_23d3f509 | 2026-02-24 |